XNASRAPP
Market cap610mUSD
Jan 08, Last price
16.69USD
1D
-6.16%
1Q
-18.23%
IPO
-36.27%
Name
Rapport Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-35m
L+226.57%
CFO
-27m
L+738.40%
Profile
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2023‑12 | 2022‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | 36,179 | 9,130 |
Unusual Expense (Income) | ||
NOPBT | (36,179) | (9,130) |
NOPBT Margin | ||
Operating Taxes | 10 | |
Tax Rate | ||
NOPAT | (36,189) | (9,130) |
Net income | (34,786) 226.57% | (10,652) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 50 | 31,787 |
BB yield | ||
| Debt | ||
Debt current | 670 | |
Long-term debt | 3,622 | |
Deferred revenue | ||
Other long-term liabilities | 4,200 | 10,435 |
Net debt | (143,271) | (31,159) |
| Cash flow | ||
Cash from operating activities | (27,181) | (3,242) |
CAPEX | (1,636) | (284) |
Cash from investing activities | (78,860) | (5,284) |
Cash from financing activities | 145,136 | 39,685 |
FCF | (39,854) | |
| Balance | ||
Cash | 147,563 | 31,159 |
Long term investments | ||
Excess cash | 147,563 | 31,159 |
Stockholders' equity | 121,148 | 18,915 |
Invested Capital | 26,142 | 11,025 |
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | 164,353 | 36,576 |
Price | ||
Market cap | ||
EV | ||
EBITDA | (36,067) | (9,115) |
EV/EBITDA | ||
Interest | 285 | |
Interest/NOPBT | ||